TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8717309

Group type: EXPERIMENTAL
Intervention: Steroid therapy (prednisolone 20‐60 mg/day orally, or pulse therapy)
Number of subjects: 51
Study: 1908630

Group type: EXPERIMENTAL
Intervention: Slow-release nifedipine (20 mg at 10 P.M. or 2 doses of 20 mg at 10 P.M. and 6 A.M.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nifedipine therapy
Number of subjects: 15
Study: 6815153

Group type: EXPERIMENTAL
Intervention: Multiple contact procedure (postcard and two telephone call reminders)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Incentive procedure (selecting among four gifts contingent on seeking care)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Incentive + problem-solve procedure (combination of incentive and problem-solve techniques)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control procedure (parents given a dentist's name)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intensive strategies (multiple contact, incentive, and incentive + problem-solve)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Multiple contact technique
Number of subjects: 125
Study: 31721914

Group type: EXPERIMENTAL
Intervention: Antibiotic in the diet (0.01 g kg‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotic in the water (0.002 g L‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercial probiotic (Saccharomyces cerevisiae) in the diet (1 g Kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (water and diet without additives)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotic in the water and yeast in the diet (0.002 g L‐1 and 1 g Kg‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yeast in the diet (1 g Kg‐1)
Number of subjects: 0
Study: 27827824

Group type: EXPERIMENTAL
Intervention: Tacrolimus/sirolimus (Tac/Sir)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Tacrolimus/methotrexate (Tac/Mtx)
Number of subjects: 211
Study: 25808099

Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery (SCS)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 135
Study: 24028201

Group type: EXPERIMENTAL
Intervention: Strength exercise group
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Cycling group
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group (doing as usual)
Number of subjects: 207
Study: 21834707

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20% carbamide peroxide (CP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 35% carbamide peroxide (CP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All bleaching systems tested
Number of subjects: 60
Study: 19108951

Group type: EXPERIMENTAL
Intervention: ACT (Acceptance and Commitment Therapy)
Number of subjects: 32

Group type: COMPARATOR
Intervention: MDT (Multidisciplinary Treatment)
Number of subjects: 32
Study: 16574123

Group type: EXPERIMENTAL
Intervention: Peripheral intravenous cannulas re‐sited only when complications occurred
Number of subjects: 206

Group type: COMPARATOR
Intervention: Peripheral intravenous cannulas re‐sited every 3 days
Number of subjects: 206
Study: 15475527

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) infusion during rhythmic handgrip (RHG) exercise
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline control during rhythmic handgrip (RHG) exercise
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Passive exercise in HF patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Passive exercise in healthy controls
Number of subjects: 25
Study: 16305056

Group type: EXPERIMENTAL
Intervention: Pioglitazone plus sulphonylurea
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Pioglitazone plus metformin
Number of subjects: 177
Study: 10022494

Group type: EXPERIMENTAL
Intervention: Visual instruction cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory trigger stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Movement-related responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instruction cue and sustained activity during delay
Number of subjects: 0
Study: 7479391

Group type: EXPERIMENTAL
Intervention: Prostate specific antigen (PSA) levels
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Prostate specific antigen density (PSAD)
Number of subjects: 502
Study: 2404805

Group type: EXPERIMENTAL
Intervention: Gestrinone 1.25 mg twice weekly (group I)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gestrinone 2.5 mg twice weekly (group II)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both doses of gestrinone
Number of subjects: 12
Study: 6991101

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 79

Group type: COMPARATOR
Intervention: Fluoxymesterone
Number of subjects: 79
Study: 30570303

Group type: EXPERIMENTAL
Intervention: Dissonance-based Body Project treatment (BPT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Supportive mindfulness treatment
Number of subjects: 84
Study: 28265678

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg daily for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25948780

Group type: EXPERIMENTAL
Intervention: Bacillus coagulans GBI-30, 6086 (BC30)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 36
Study: 25022156

Group type: EXPERIMENTAL
Intervention: UL+RE (N = 10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: UL (N = 11)
Number of subjects: 21
Study: 22972300

Group type: EXPERIMENTAL
Intervention: Political mobilization messages delivered via Facebook
Number of subjects: 61000000

Group type: EXPERIMENTAL
Intervention: Social transmission effects from users who received messages
Number of subjects: 61000000
Study: 19179916

Group type: EXPERIMENTAL
Intervention: Graded exercise intervention emphasizing stabilizing exercises
Number of subjects: 71

Group type: COMPARATOR
Intervention: Daily walks
Number of subjects: 71
Study: 17524208

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients in tasks 1 and 2
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy controls in tasks 1 and 2
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients in task 3
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy controls in task 3
Number of subjects: 37
Study: 15712714

Group type: EXPERIMENTAL
Intervention: Reaction-board measurement method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Segmental method
Number of subjects: 0
Study: 11852293

Group type: EXPERIMENTAL
Intervention: Theophylline (10-20 microg/mL after 15 days of treatment)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9826292

Group type: EXPERIMENTAL
Intervention: Mirror presence
Number of subjects: 43

Group type: COMPARATOR
Intervention: No mirror
Number of subjects: 43
Study: 7801180

Group type: EXPERIMENTAL
Intervention: Clinical diagnostic tests and procedures for spinal disorders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Main study approaches in outcomes research
Number of subjects: 0
Study: 31502676

Group type: EXPERIMENTAL
Intervention: Original method for generating null distributions of statistics pertaining to differences in G matrices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified method for generating null distributions of statistics pertaining to differences in G matrices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real data set analysis using both methods
Number of subjects: 0
Study: 29229086

Group type: EXPERIMENTAL
Intervention: Ground-based walking training (supervised, 2-3 times per week for 8-10 weeks)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (usual medical care)
Number of subjects: 143
Study: 26362226

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (800 mg calcium and 400 IU vitamin D daily for 6 months)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 17
Study: 23680679

Group type: EXPERIMENTAL
Intervention: 8-week, twice weekly exercise program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual-care control (CON) group
Number of subjects: 60
Study: 21052731

Group type: EXPERIMENTAL
Intervention: Preoperative education
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control condition (no preoperative education)
Number of subjects: 96
Study: 17146375

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention (15 sessions, 90 minutes each, divided into 3 modules: stress, coping, and adjustment; safer behaviors; and health behaviors)
Number of subjects: 936

Group type: COMPARATOR
Intervention: Control group (no intervention until trial completion)
Number of subjects: 936
Study: 15854942

Group type: EXPERIMENTAL
Intervention: Preoperative methylene blue administration (2 mg/kg intravenously for more than 30 minutes, starting 1 hour before surgery)
Number of subjects: 100
Study: 12217418

Group type: EXPERIMENTAL
Intervention: Nociceptin (200pmol) administered into tender non-dominant trapezius muscles
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nociceptin administered into temporal muscle (open labeled design)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (control group for the 10 subjects)
Number of subjects: 14
Study: 10731128

Group type: EXPERIMENTAL
Intervention: UVB phototherapy plus tazarotene
Number of subjects: 10

Group type: COMPARATOR
Intervention: UVB phototherapy alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: UVB phototherapy plus vehicle gel
Number of subjects: 10
Study: 8749244

Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg subcutaneously
Number of subjects: 138

Group type: COMPARATOR
Intervention: Sumatriptan 12 mg subcutaneously
Number of subjects: 138
Study: 2380574

Group type: EXPERIMENTAL
Intervention: Photoreactivating light from BLB fluorescent lamps (UVA radiation)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Photoreactivating light from incandescent bulbs (visible light)
Number of subjects: 8

Group type: COMPARATOR
Intervention: UVB radiation exposure
Number of subjects: 8
Study: 6779150

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide at a 20% concentration in an oil-in-water emulsion (Benoxyl 20)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30871632

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adaptive Pacing Therapy (APT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Specialized Medical Care
Number of subjects: 0
Study: 28157140

Group type: EXPERIMENTAL
Intervention: Emergency department ventilator protocol targeting lung-protective tidal volume, positive end-expiratory pressure, oxygen weaning, and head-of-bed elevation.
Number of subjects: 229

Group type: COMPARATOR
Intervention: Preintervention group (control)
Number of subjects: 229
Study: 25704236

Group type: EXPERIMENTAL
Intervention: Loaded miniscrews
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unloaded miniscrews
Number of subjects: 20
Study: 23962535

Group type: EXPERIMENTAL
Intervention: Abatacept (N=71)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo (N=34)
Number of subjects: 115
Study: 21864830

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 64
Study: 19444560

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg x kg(‐1) i.v. bolus 30 min before induction, followed by an infusion of 1.5 mg x kg(‐1) x h(‐1) until 1 h after surgery (n = 45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline placebo (n = 45)
Number of subjects: 90
Study: 17679315

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS), details on dosage and duration not specified
Number of subjects: 0
Study: 15020290

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms (SNPs) in the IL1RN gene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequencing approach to the coding region of the IL1RN gene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haplotype analysis of six SNPs
Number of subjects: 0
Study: 12465163

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise program
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Combination of supervised exercise program and group education
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Self-management education program
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study: 9690103

Group type: EXPERIMENTAL
Intervention: Intervention work sites
Number of subjects: 11237

Group type: COMPARATOR
Intervention: Control work sites
Number of subjects: 11237
Study: 8126497

Group type: EXPERIMENTAL
Intervention: Active treatment (total lymphoid irradiation, TLI)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Active treatment (TLI)
Number of subjects: 27
Study: 2551008

Group type: EXPERIMENTAL
Intervention: Flunarizine i.v.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 1117404

Group type: EXPERIMENTAL
Intervention: High stress - common fate (both awaiting electric shock)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High stress - dissimilar fate (subject awaiting electric shock, confederate awaiting innocuous word association)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low stress - dissimilar fate (subject awaiting word association, confederate awaiting shock)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low stress - common fate (both awaiting innocuous word association)
Number of subjects: 0
Study: 31895945

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW)‐led group‐based education and monitoring intervention, conducted fortnightly for 3 months.
Number of subjects: 637

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW)‐led group‐based education and monitoring intervention
Number of subjects: 637
Study: 30657995

Group type: EXPERIMENTAL
Intervention: MIRT (Multidisciplinary Intensive Rehabilitation Treatment)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MIRT-AT (MIRT with Aquatic Therapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MIRT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MIRT-AT
Number of subjects: 60
Study: 29217004

Group type: EXPERIMENTAL
Intervention: Transapical (TA) TAVR
Number of subjects: 2084

Group type: COMPARATOR
Intervention: Transfemoral (TF) TAVR
Number of subjects: 2084
Study: 26018633

Group type: EXPERIMENTAL
Intervention: Early invitation to food supplementation combined with multiple micronutrient supplements (MMS) including 30 mg iron and 400 μgm folic acid.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual invitation to food supplementation combined with 60 mg iron and 400 μgm folic acid (UFe60F).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incrementing UFe60F to EMMS.
Number of subjects: 0
Study: 24334857

Group type: EXPERIMENTAL
Intervention: Autologous high‐molecular‐weight plasma protein fraction therapy (AHPT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Autologous plasma therapy (APT)
Number of subjects: 22
Study: 23102619

Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation (75 mg/day for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 17916183

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg/every other day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17888975

Group type: EXPERIMENTAL
Intervention: CorCap Cardiac Support Device
Number of subjects: 300
Study: 15871025

Group type: EXPERIMENTAL
Intervention: Cataract surgery with foldable lens implantation
Number of subjects: 71
Study: 11952923

Group type: EXPERIMENTAL
Intervention: Group musical therapy (15 sessions over 4 months)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Waiting group (control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Group musical therapy
Number of subjects: 66
Study: 10215959

Group type: EXPERIMENTAL
Intervention: HIV-induced immunodeficiency with hepatitis virus co-infection
Number of subjects: 6
Study: 8583662

Group type: EXPERIMENTAL
Intervention: Aprotinin (apr) 10(6) KIU infused immediately after anesthesia, before and after ECC, and during ECC (Group I)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Aprotinin (apr) 10(6) KIU infused before and at three hours after ECC, and 2 x 10(6) KIU immediately after ECC (Group II)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (Group II)
Number of subjects: 14
Study: 2354476

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Recombinant tissue type plasminogen activator
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conservative treatment (no thrombolytic therapy)
Number of subjects: 65
Study: 391176

Group type: EXPERIMENTAL
Intervention: Mepartricin (SPA‐S‐160 enteric‐coated tablets)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clofibrate
Number of subjects: 20
Study: 29215478

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 27258938

Group type: EXPERIMENTAL
Intervention: Eugluc‐Hiinsu clamp with GIP infusion (1.5 pmol/kg/min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hyperglycemic‐hyperinsulinemic clamp with GIP infusion (1.5 pmol/kg/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hygluc‐Euinsu clamp
Number of subjects: 6
Study: 25024629

Group type: EXPERIMENTAL
Intervention: I.31 high dose (n = 28)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: I.31 low dose (n = 27)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: I.31 high dose
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: I.31 low dose
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 22050270

Group type: EXPERIMENTAL
Intervention: Half-body fractional CO(2) laser therapy followed by NB‐UVB phototherapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: NB‐UVB alone
Number of subjects: 10
Study: 20920436

Group type: EXPERIMENTAL
Intervention: Inhaled FDKP (20 mg) in DNP subjects
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Inhaled FDKP (20 mg) in subjects with normal renal function
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Inhaled FDKP (20 mg) in healthy subjects
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Inhaled FDKP (20 mg) in CLD subjects
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Intravenous FDKP
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Oral FDKP
Number of subjects: 69
Study: 18576358

Group type: EXPERIMENTAL
Intervention: Reciprocating Procedure Device (RPD)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Safety needle
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Reciprocating Procedure Device (RPD) combined with safety needle
Number of subjects: 566

Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 566
Study: 15814861

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 256

Group type: COMPARATOR
Intervention: Stretching Control
Number of subjects: 256
Study: 12219858

Group type: EXPERIMENTAL
Intervention: Increasing the salience of social categorization at any level of the hierarchy (6 individuals, 2 subgroups, 1 collective)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individuating the members of the individuals' own subgroup and/or the opposing subgroup
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross-categorization with the opposing subgroup
Number of subjects: 0
Study: 10505152

Group type: EXPERIMENTAL
Intervention: Laser stapedotomy
Number of subjects: 34
Study: 8751847

Group type: EXPERIMENTAL
Intervention: Radioisotope stents (phosphorus-32)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Catheter-based radiation therapies
Number of subjects: 0
Study: 1999372

Group type: EXPERIMENTAL
Intervention: Active therapy
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study: 6949928

Group type: EXPERIMENTAL
Intervention: Chlorhexidine irrigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo irrigation
Number of subjects: 0
Study: 31337173

Group type: EXPERIMENTAL
Intervention: Pectoral nerve block I (PECS I) + Serratus-intercostal plane block (SPB)
Number of subjects: 61

Group type: COMPARATOR
Intervention: General anesthesia only (Control group)
Number of subjects: 61
Study: 27704317

Group type: EXPERIMENTAL
Intervention: PVI + RSD
Number of subjects: 236

Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 236

Group type: COMPARATOR
Intervention: PVI (normal renal function)
Number of subjects: 236
Study: 25786369

Group type: EXPERIMENTAL
Intervention: AMG 416 (10 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AMG 416 (5 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24120932

Group type: EXPERIMENTAL
Intervention: High protein diet (3gkg(‐1)proteinBM(‐1)day(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal diet (1.5gkg(‐1)proteinBM(‐1)day(‐1))
Number of subjects: 8
Study: 22054204

Group type: EXPERIMENTAL
Intervention: MEL 308 nm + oral vitamin E
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: MEL 308 nm + 0.1% tacrolimus + oral vitamin E
Number of subjects: 53

Group type: COMPARATOR
Intervention: Oral vitamin E
Number of subjects: 53
Study: 19602250

Group type: EXPERIMENTAL
Intervention: Active acupuncture treatment (real acupuncture), 3 times per week for 12 sessions over 4 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture treatment, 3 times per week for 12 sessions over 4 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group, no treatment during the 4 weeks, only recording symptoms in a daily diary.
Number of subjects: 0
Study: 17496402

Group type: EXPERIMENTAL
Intervention: Antibiotic lock therapy using vancomycin and gentamycin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Routine TCC management
Number of subjects: 63